Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
In Vivo Transfection Rat Small Intestine K-Cell With Pgip/Ins Plasmid by Dotap Liposome Publisher Pubmed



Palizban AA1 ; Salehi R2 ; Nori N3 ; Galehdari H3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Biochemistry, Faculty of Pharmacy, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran
  2. 2. Department of Clinical Genetics, Faculty of Medicine, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran
  3. 3. Department of Genetics, Faculty of Science, University of Shahid Chamran, Ahvaz, Iran

Source: Journal of Drug Targeting Published:2007


Abstract

Gene therapies to produce insulin in diabetic patients have been considered for several years. Genetic engineering of ectopic insulin production and secretion in autologous non-beta-cells has been tested in different tissues. Recently, gut K-cells have been shown to express glucokinase, the glucose sensor of pancreatic beta-cells. K-cells are responsible for the secretion of the glucose-dependent insulinotropic peptide (GIP). Transfection of K-cells by a specific plasmid to produce insulin correlated to glucose level is being considered. Cationic liposomes are non-viral gene delivery to lung, spleen, liver and intestinal cells. DOTAP-GIP/Ins plasmid complex was used for transfection of K-cells in vivo. RT-PCR assay of human insulin mRNA revealed that the transfection of insulin gene by DOTAP liposome is an efficient tool. The genetic engineering of ectopic insulin production and secretion in autologous non-beta-cells is an appropriate method. The potential of the transmission of a constructed plasmid, which contains human insulin gene under the control of GIP promoter, to gut K-cells could be considered for treatment of diabetes.